Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Despite positive Phase III clinical trial data for Allergan’s age-related macular degeneration drug, investors weren’t as positive about it.
La Jolla, California-based Human Longevity, Inc. (HLI) filed a lawsuit against the J. Craig Venter Institute (JCVI). Although Venter himself is at the center of the suit, he is not personally being sued.
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
The U.S. Food and Drug Administration is looking to address supply chain threats by potentially importing foreign drugs under a narrow scope.
In a speech given at the Brookings Institution preceding the release of the U.S. Food and Drug Administration (FDA)’s Biosimilars Action Plan, FDA Commissioner Scott Gottlieb unloaded on big pharma.
In 2012, the U.S. Food and Drug Administration (FDA) created Breakthrough Therapy designation. The Washington Post reports on a new study conducted by Yale School of Medicine researchers and published in the Journal of the American Medical Association that looks at the designation and the drugs that received it.
Swiss pharma giant Novartis is halting planned price increases on its medications after President Donald Trump took Pfizer to task over price hikes earlier this month. Pfizer agreed to roll back its price increases last week.
Shares of Cambridge, Mass.-based Spero Therapeutics are climbing this morning after the company announced it secured up to $54 million from the government to support its development of SPR944 as a potential treatment against drug-resistant infections.
The U.S. Food and Drug Administration (FDA) is warning consumers who seek to buy medications through websites that they may be opening themselves up to of a swarm of imposters claiming to be representatives of the regulatory agency.
Saturnino “Nino” Fanlo, chief financial officer and chief operations officer of Human Longevity (HLI), has left the company. Fanlo was implicated in a scandal at his previous employer, online lender Social Finance (SoFi).